GALT:NAS (USA) Also trade in: Germany

Galectin Therapeutics Inc

$ 4.78 0 (0%)
Volume: 1,049,394 Avg Vol (1m): 405,361
Market Cap $: 217.73 Mil Enterprise Value $: 218.42 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value 0.7
Net Current Asset Value -0.05
Tangible Book -0.05
Projected FCF -3.19
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 7/10

Current vs industry vs history
Cash-to-Debt No Debt
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 25.32
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 31.07%

Profitability & Growth : 4/10

Current vs industry vs history
ROE % -255.16
ROA % -174.08
3-Year Total EBITDA Growth Rate 12.20
3-Year EPS w/o NRI Growth Rate 24.40

» GALT's 30-Y Financials

Financials (Next Earnings Date: 2019-05-10)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:GALT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare ROCO:6535 TSXV:ICC DHA:ORIONPHARM BOM:590006 ROCO:6620 XCNQ:TER NAS:EYPT TSXV:WMD XKRX:220100 LSE:SPH ASX:EXL OTCPK:OPTI BOM:531146 XKRX:009300 TSX:IN NAS:ADMP MIL:PHN ROCO:6496 ROCO:6472 TSXV:RX
Traded in other countries PHPN.Germany
Address 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a biotechnology company. The company is focused on discovery and development. It is engaged in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis.

Ratios

Current vs industry vs history
EV-to-EBIT -16.10
EV-to-EBITDA -16.10
Current Ratio 4.19
Quick Ratio 4.19

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -15.90

Valuation & Return

Current vs industry vs history
Earnings Yield (Joel Greenblatt) % -6.22

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N